VIVXF (Avivagen) Cyclically Adjusted Revenue per Share: $0.01 (As of Jul. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Avivagen Cyclically Adjusted Revenue per Share?

Avivagen VIVXF -99.00% Cyclically Adjusted Revenue per Share is $0.01 as of Jul. 2023.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Avivagen's adjusted revenue per share for the three months ended in Jul. 2023 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.01 for the trailing ten years ended in Jul. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-13), Avivagen's current stock price is $0.0001. Avivagen's Cyclically Adjusted Revenue per Share for the quarter that ended in Jul. 2023 was $0.01. Avivagen's Cyclically Adjusted PS Ratio of today is 0.01.


Avivagen  (OTCPK:VIVXF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Avivagen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.0001/0.01
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Avivagen Cyclically Adjusted Revenue per Share Related Terms


Avivagen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Avivagen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Cyclically Adjusted Revenue per Share Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.02 0.03 0.00 0.02

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.01 0.01

VIVXF vs DMKPQ, MJNE, ACORQ: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avivagen Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Avivagen's Cyclically Adjusted PS Ratio falls into.



Avivagen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Avivagen's adjusted Revenue per Share data for the three months ended in Jul. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jul. 2023 (Change)*Current CPI (Jul. 2023)
=0/124.9144*124.9144
=0.000

Current CPI (Jul. 2023) = 124.9144.

Avivagen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201310 0.001 97.182 0.001
201401 0.009 97.261 0.012
201404 0.002 98.920 0.003
201407 0.002 99.315 0.003
201410 0.002 99.473 0.003
201501 0.001 98.209 0.001
201504 0.003 99.710 0.004
201507 0.001 100.579 0.001
201510 0.002 100.500 0.002
201601 0.001 100.184 0.001
201604 0.002 101.370 0.002
201607 0.002 101.844 0.002
201610 -0.003 102.002 -0.004
201701 0.001 102.318 0.001
201704 0.000 103.029 0.000
201707 0.004 103.029 0.005
201710 0.002 103.424 0.002
201801 0.004 104.056 0.005
201804 0.005 105.320 0.006
201807 0.008 106.110 0.009
201810 0.008 105.952 0.009
201901 0.007 105.557 0.008
201904 0.007 107.453 0.008
201907 0.000 108.243 0.000
201910 0.007 107.927 0.008
202001 0.005 108.085 0.006
202004 0.001 107.216 0.001
202007 0.011 108.401 0.013
202010 0.005 108.638 0.006
202101 0.005 109.192 0.006
202104 0.002 110.851 0.002
202107 0.012 112.431 0.013
202110 0.000 113.695 0.000
202201 0.004 114.801 0.004
202204 0.001 118.357 0.001
202207 0.001 120.964 0.001
202210 0.009 121.517 0.009
202301 0.001 121.596 0.001
202304 0.001 123.571 0.001
202307 0.000 124.914 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.01 mean?
Avivagen (VIVXF) has a Cyclically Adjusted Revenue per Share of $0.01 as of Jul. 2023. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Avivagen and its competitors.
Is Avivagen's Cyclically Adjusted Revenue per Share too high?
Avivagen's current Cyclically Adjusted Revenue per Share is $0.01.
How does Avivagen's Cyclically Adjusted Revenue per Share compare to DMKPQ and MJNE?
Avivagen's Cyclically Adjusted Revenue per Share of $0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Avivagen and its competitors. Avivagen's current Cyclically Adjusted Revenue per Share is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current Cyclically Adjusted Revenue per Share of $0.01. The current Cyclically Adjusted Revenue per Share is $0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Avivagen (VIVXF), the current Cyclically Adjusted Revenue per Share is $0.01 as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.